These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 20009532)

  • 1. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
    Zhao L; Vogt PK
    Cell Cycle; 2010 Feb; 9(3):596-600. PubMed ID: 20009532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.
    Zhao L; Vogt PK
    Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2652-7. PubMed ID: 18268322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.
    Hao Y; Wang C; Cao B; Hirsch BM; Song J; Markowitz SD; Ewing RM; Sedwick D; Liu L; Zheng W; Wang Z
    Cancer Cell; 2013 May; 23(5):583-93. PubMed ID: 23643389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
    Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
    Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human tumor mutants in the p110alpha subunit of PI3K.
    Liu Z; Roberts TM
    Cell Cycle; 2006 Apr; 5(7):675-7. PubMed ID: 16627990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.
    Dbouk HA; Pang H; Fiser A; Backer JM
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):19897-902. PubMed ID: 21030680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
    Huang CH; Mandelker D; Gabelli SB; Amzel LM
    Cell Cycle; 2008 May; 7(9):1151-6. PubMed ID: 18418043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
    Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
    Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
    Pang H; Flinn R; Patsialou A; Wyckoff J; Roussos ET; Wu H; Pozzuto M; Goswami S; Condeelis JS; Bresnick AR; Segall JE; Backer JM
    Cancer Res; 2009 Dec; 69(23):8868-76. PubMed ID: 19903845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.
    Miled N; Yan Y; Hon WC; Perisic O; Zvelebil M; Inbar Y; Schneidman-Duhovny D; Wolfson HJ; Backer JM; Williams RL
    Science; 2007 Jul; 317(5835):239-42. PubMed ID: 17626883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galphaq binds to p110alpha/p85alpha phosphoinositide 3-kinase and displaces Ras.
    Ballou LM; Chattopadhyay M; Li Y; Scarlata S; Lin RZ
    Biochem J; 2006 Mar; 394(Pt 3):557-62. PubMed ID: 16268778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase.
    Sun M; Hart JR; Hillmann P; Gymnopoulos M; Vogt PK
    Cell Cycle; 2011 Nov; 10(21):3731-9. PubMed ID: 22045127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Class I PI3K in oncogenic cellular transformation.
    Zhao L; Vogt PK
    Oncogene; 2008 Sep; 27(41):5486-96. PubMed ID: 18794883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
    Huang CH; Mandelker D; Schmidt-Kittler O; Samuels Y; Velculescu VE; Kinzler KW; Vogelstein B; Gabelli SB; Amzel LM
    Science; 2007 Dec; 318(5857):1744-8. PubMed ID: 18079394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants.
    Wu H; Shekar SC; Flinn RJ; El-Sibai M; Jaiswal BS; Sen KI; Janakiraman V; Seshagiri S; Gerfen GJ; Girvin ME; Backer JM
    Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20258-63. PubMed ID: 19915146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).
    Burke JE; Perisic O; Masson GR; Vadas O; Williams RL
    Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15259-64. PubMed ID: 22949682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rare cancer-specific mutations in PIK3CA show gain of function.
    Gymnopoulos M; Elsliger MA; Vogt PK
    Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5569-74. PubMed ID: 17376864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
    Echeverria I; Liu Y; Gabelli SB; Amzel LM
    FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic mutations of PIK3CA in human cancers.
    Samuels Y; Velculescu VE
    Cell Cycle; 2004 Oct; 3(10):1221-4. PubMed ID: 15467468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic signaling of class I PI3K isoforms.
    Denley A; Kang S; Karst U; Vogt PK
    Oncogene; 2008 Apr; 27(18):2561-74. PubMed ID: 17998941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.